GSK makes structures of potential antimalarials freely availableBMJ 2010; 340 doi: http://dx.doi.org/10.1136/bmj.c465 (Published 25 January 2010) Cite this as: BMJ 2010;340:c465
- Jacqui Wise
GlaxoSmithKline has announced that it will make the chemical structures of 13 500 compounds with potential antimalarial activity freely available on scientific websites to encourage research into new drugs for malaria.
The company says it has screened its pharmaceutical compound library of more than two million molecules for any that inhibit the malaria parasite Plasmodium falciparum. The company says this process took five scientists a year to complete.
Andrew Witty, chief executive of GSK, announced his “Open Innovation” strategy in a speech given at the Council on Foreign Relations in New York on 20 January. As well as opening up access to these potential antimalarial compounds, the company has set up an “open lab,” which will be part of its research centre in Tres Cantos, near Madrid. The laboratory will have capacity for up to 60 independent researchers to pursue their own projects as part of a drug discovery …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial